Prevalence and predictors of substance abuse among patients with depressive and anxiety disorders: a cross-sectional study at a tertiary care hospital in Udaipur

Sushil Kherada; Suresh Chand Gochar; Shelesh Kumar Swami; Nitesh Kumar Chauhan; A. K. Verma

doi:10.18203/2394-6040.ijcmph20264064

Authors

Sushil Kherada Department of Psychiatry, Pacific Medical College and Hospital, Udaipur, Rajasthan, India https://orcid.org/0009-0005-4784-2138
Suresh Chand Gochar Department of Psychiatry, Pacific Medical College and Hospital, Udaipur, Rajasthan, India https://orcid.org/0009-0000-8681-6665
Shelesh Kumar Swami Scientist-C, Multi-disciplinary Research Unit, RNT Medical College, Udaipur, Rajasthan, India
Nitesh Kumar Chauhan Scientist-B, Multi-disciplinary Research Unit, RNT Medical College, Udaipur, Rajasthan, India https://orcid.org/0009-0002-7886-4493
A. K. Verma Department of Biochemistry, RNT Medical College, Udaipur, Rajasthan, India https://orcid.org/0009-0005-6401-6479

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20264064

Keywords:

Depression, Comorbidity, Substance abuse, Anxiety disorders, Urine drug screening, Mental health

Abstract

Background: Substance abuse is a serious public health concern among individuals with psychiatric disorders, particularly anxiety and depression. However, data on its prevalence and association with symptom severity in Indian patients remain limited. This study aimed to determine the prevalence of substance abuse among patients with anxiety and depressive disorders and to evaluate its association with symptom severity.

Methods: A cross-sectional study was conducted on 162 participants diagnosed with anxiety or depressive disorders. Data were collected on socio-demographic factors, psychiatric diagnosis, and substance use through standardized tools and urine drug screening. Severity of disorders was assessed using standard clinical rating scales. Symptom severity was evaluated using the Hamilton Depression Rating Scale (HAM-D) and the Hamilton Anxiety Rating Scale (HAM-A).

Results: The majority of participants were male 119 (73.5%) and belonged primarily to the upper lower socio-economic class 68 (42.0%). Benzodiazepines 19 (11.7%) were the most frequently found substance, followed by tricyclic antidepressants 13 (8.0%) and Alcohol 8 (4.9%). Substance abuse prevalence was higher among participants with profound depression 11 out of 19 (57.9%) and among those participants with moderate anxiety 15 out of 48 (31.3%). No statistically significant difference was observed in overall substance abuse prevalence between depressive disorders 33/98 (33.7%) and anxiety disorders 18/64 (28.1%) (p=0.457).

Conclusions: Substance abuse is common among patients with anxiety and depressive disorders, particularly in severe depressive depression. It is essential to address comorbid substance use in psychiatric populations through early detection and integrated management strategies.

References

Rehm J, Shield KD. Global burden of disease and the impact of mental and addictive disorders. Curr Psychiatr Rep. 2019;21(2):10.

World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: WHO; 2017.

Lai HM, Cleary M, Sitharthan T, Hunt GE. Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990-2014: a systematic review and meta-analysis. Drug Alcohol Depend. 2015;154:1-13.

Volkow ND. Substance use disorders in schizophrenia- clinical implications of comorbidity. Schizophr Bull. 2009;35(3):469-72.

Grant BF, Stinson FS, Dawson DA, Chou SP, Ruan WJ, Pickering RP. Co-occurrence of 12-month alcohol and drug use disorders and personalitydisorders in the United States: results from the National Epidemiologic Survey on Alcohol and RelatedConditions. Arch Gen Psychiatr. 2004;61(4):361-8.

Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA. 1990;264(19):2511-8.

Khantzian EJ. The self-medication hypothesis of addictive disorders: Focus on heroin and cocaine dependence. Am J Psychiatr. 1997;152(4):1259-64.

Smith JP, Book SW. Anxiety and substance use disorders: a review. Psychiatr Clin North Am. 2008;31(2):243-59.

World Health Organization. The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.

Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr. 1960;23:56-62.

Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-5.

Davis L, Uezato A, Newell JM, Frazier E. Major depression and comorbid substance use disorders. Curr Opin Psychiatr. 2008;21(1):14-8.

Longo LP, Johnson B. Addiction: Part I. Benzodiazepines- side effects, abuse risk and alternatives. Am Fam Phys. 2000;61(7):2121-8.

Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376(12):1147-57.

Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151:737-48.

Buckner JD, Heimberg RG, Schmidt NB. Social anxiety and marijuana-related problems: the role of social avoidance. Addict Behav. 2011;36(1-2):129-32.

Bolton JM, Robinson J, Sareen J. Self-medication of mood disorders with alcohol and drugs in the National Epidemiologic Survey on Alcohol and Related Conditions. J Affect Disord. 2009;115(3):367-75.

Feingold D, Weiser M, Rehm J, Lev-Ran S. The association between cannabis use and anxiety disorders: results from a population-based representative sample. Eur Neuropsychopharmacol. 2016;26(3):493-505

Goldstein BI, Levitt AJ. The specific burden of comorbid anxiety disorders and of substance use disorders in bipolar I disorder. Bipolar Disord. 2008;10(1):67-78.

Smith JP, Book SW. Anxiety and substance use disorders: A review. Psychiatr Times. 2008;25(10):19.

National Mental Health Survey of India, 2015-16. Bengaluru: NIMHANS Publication No. 129; 2016.

Galea S, Ahern J, Tracy M, Vlahov D. Neighborhood income and income distribution and the use of cigarettes, alcohol, and marijuana. Am J Prev Med. 2007;32(6):S195-202.

Hatch SL, Dohrenwend BP. Distribution of traumatic and other stressful life events by race/ethnicity, gender, SES and age: a United States population study. Soc Psychiatr Psychiatr Epidemiol. 2007;42(8):627-34.

Cosci F, Fava GA. New clinical strategies of benzodiazepine treatment. Psychother Psychosom. 2011;80(5):265-70.

Drake RE, Wallach MA. Dual diagnosis: 15 years of progress. Psychiatr Serv. 2000;51(9):1126-9.

McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689-95.